secwatch.observer — SEC 8-K summary
======================================

Issuer:     EQRx, Inc. (—)
CIK:        0001843762
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001104659-23-024512
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EQRx Q4 net loss $22.2M, full year $169.1M; cuts headcount 18% to ~300 employees
--------------------------------------------------------------------------------

- Net loss Q4 2022 $22.2M vs net income $1.2M in Q4 2021; full year net loss $169.1M vs $100.0M in 2021.
- Cash, cash equivalents and short-term investments $1.4B at Dec 31, 2022; runway into 2028.
- 2023 cash used in operations expected <$275M.
- Restructuring: 18% headcount reduction to ~300 employees by end of Q1 2023; expected annualized cash savings ~$18M; one-time costs ~$4M.
- Pipeline: MAAs for aumolertinib and sugemalimab accepted by MHRA and EMA; Phase 3 trial for lerociclib in endometrial cancer expected 1H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1843762/000110465923024512/0001104659-23-024512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1843762/000110465923024512/tm237658d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-024512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer